Artificial Intelligence
Gritstone Oncology Advances into Phase 2 Expansion Cohorts for its Personalized Neoantigen Immunotherapy GRANITE and its Off-the-Shelf Neoantigen Immunotherapy SLATE
—The Phase 1 portions of the studies are closed for enrollment; patient treatment and follow-up for efficacy and safety continues—
EMERYVILLE, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) — Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that it has begun dosing patients in the Phase 2 expansion cohorts of the Phase 1/2 clinical studies for GRANITE and SLATE, its neoantigen-based immunotherapies.
“We are excited to advance the highest doses of GRANITE and SLATE tested in the Phase 1 studies into Phase 2 clinical cohorts and interrogate the ability of our immunotherapies at full dose to elicit robust immune responses against historically cold (or non-immunogenic) tumor types such as metastatic colorectal cancer,” said Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer of Gritstone Oncology. “We have seen promising data in our Phase 1 study, which is still ongoing, including in gastro-esophageal and colorectal cancers, and we look forward to presenting the full dataset by mid-2021. Additionally, we continue to remain highly interested in the adjuvant setting where immunotherapy is likely to have the greatest impact and where diagnostic blood tests such as circulating tumor DNA (ctDNA) can be employed to run efficient trials in patients in need.”
Daniel Catenacci, M.D., director of the Gastrointestinal Oncology Program at the University of Chicago Medicine and principal investigator on the studies, added, “The early Phase 1 data clearly show robust induction of neoantigen-specific CD8+ T cells, expansion of those cells in the tumor microenvironment, and early evidence of benefit to our patients. Delivering effective immunotherapy to patients with cold tumors would change the landscape of cancer treatment and expand the role of immunotherapy significantly.”
The Phase 2 portion of the GRANITE Phase 1/2 study (GO-004) includes a cohort for patients with microsatellite stable colorectal cancer (MSS CRC) who have progressed on FOLFOX/FOLFIRI therapy and a second cohort for patients with gastro-esophageal cancer (GEA) who have progressed on chemotherapy. GRANITE was granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of MSS CRC.
In the Phase 2 part of the SLATE Phase 1/2 study (GO-005), the company has begun enrolling non-small cell lung cancer patients with relevant KRAS mutations who have progressed on prior immunotherapy, and patients with tumors where a relevant TP53 mutation exists.
Raphaël Rousseau, M.D., Ph.D., executive vice president and chief medical officer of Gritstone Oncology, added, “These expansion cohorts are designed to rapidly and unambiguously identify efficacy signals by studying patients in whom checkpoint inhibitor therapy is essentially inactive (MSS CRC) or has low activity (GEA). Furthermore, and related to the low activity of immunotherapy observed to date, patients with metastatic colorectal or gastro-esophageal cancers have poor prognoses, with estimated 12-month survival figures of only 56% and 30% respectively (SEER18 data). Registrational studies in these contexts can be consequently fast, particularly if observed treatment effects are strong.”
About GRANITE and SLATE
Gritstone’s neoantigen-based immunotherapies are engineered to elicit a significant T-cell response (particularly CD8+ cytotoxic T cells) against mutation-derived tumor-specific neoantigens, or TSNA, that are identified by the company using its proprietary Gritstone EDGETM artificial intelligence platform and tumor HLA peptide sequencing. Data demonstrating the neoantigen identification capabilities of EDGE were published in Nature Biotechnology.
GRANITE is Gritstone’s personalized immunotherapy that consists of two components: first, a priming adenoviral vector is used to deliver a cassette of 20 patient-specific TSNA derived from the patient’s own tumor; and second, the same personalized TSNA cassette is delivered using a self-amplifying RNA vector in a repeated boost sequence. GRANITE is being evaluated in combination with immune checkpoint blockade in a Phase 1/2 clinical study, referred to as GO-004. GRANITE was granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of MSS CRC.
SLATE is Gritstone’s “off-the-shelf” immunotherapy. It uses the priming adenoviral vector and self-amplifying RNA vector to deliver a cassette of 20 shared TSNA, representing mutated gene sequences that are shared across patients (such as TP53 and K-RAS mutations). SLATE is being evaluated in combination with immune checkpoint blockade in a Phase 1/2 clinical study called GO-005.
About Gritstone Oncology
Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its products by leveraging two key pillars—second, a proprietary machine learning-based platform, Gritstone EDGETM, which is designed to predict, from a routine tumor biopsy, the tumor-specific neoantigens (TSNA) that are presented on a patient’s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients’ TSNA to potentially drive the patient’s immune system to specifically attack and destroy tumors. The company’s individualized neoantigen-based immunotherapy, GRANITE, and its “off the shelf” shared neoantigen-based immunotherapy, SLATE, are being evaluated in clinical studies. Novel tumor-specific antigens can also provide targets for bispecific antibody (BiSAb) therapeutics for solid tumors, and Gritstone’s BiSAb program is currently in lead optimization. For more information, please visit gritstoneoncology.com.
Gritstone Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to the potential of Gritstone’s therapeutic programs; the advancements in the Company’s ongoing clinical trials; the timing of data announcements related to ongoing clinical trials and the initiation of future clinical trials. Such forward-looking statements involve substantial risks and uncertainties that could cause Gritstone’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including Gritstone’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Gritstone’s ability to successfully establish, protect and defend its intellectual property and other matters that could affect the sufficiency of existing cash to fund operations. Gritstone undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Gritstone’s most recent Quarterly Report on Form 10-Q filed on August 5, 2020 and any current and periodic reports filed with the Securities and Exchange Commission.
Contacts
Media:
Dan Budwick
1AB
(973) 271-6085
[email protected]
Investors:
Alexandra Santos
Wheelhouse Life Science Advisors
(510) 871-6161
[email protected]
Artificial Intelligence
Doosan Robotics Unveils Max-Powered ‘PRIME-SERIES’ of Collaborative Robots at Automate 2024
The New P-SERIES Unleashes Efficiency with a 30 Kilogram Payloadand the Longest Reach of Any Cobot to Date
CHICAGO, May 6, 2024 /PRNewswire/ — Doosan Robotics Inc., one of the world’s leading collaborative robot (cobot) manufacturers, unveiled its newest and most powerful P-SERIES (PRIME-SERIES) today at Automate 2024, bringing to the world of robotics the longest reaching cobot to date.
Today’s P-SERIES announcement by Doosan Robotics was marked by a show floor unveiling of the new P3020 – the world’s most powerful cobot for palletizing in existence. The P3020 offers a payload of 30kg (60lbs) and reach of 2,030mm (80in), bringing the ability to palletize from floor to 2m high (stacking up to 10 layers of boxes approximately 8 inches tall) using its simple fixed base without a lift.
Doosan Robotics has successfully dominated the high-payload cobot market in the 20kg range and above, which includes advanced palletizing solutions. Since launching the H-SERIES in 2022, Doosan Robotics has attracted major global customers such as Schiphol Airport and Wacker Korea, significantly enhancing its global market share by 72%. This year, with the introduction of the P-SERIES, the cobot featuring the highest payload and reach yet, expectations are set to soar beyond previous achievements.
Additional key features of the P-SERIES cobot lineup include lower power consumption compared to similar payload cobots by applying its built-in gravity compensation mechanism, inherent wrist-singularity free, and a 5 degree-of-freedom movement with the 4th axis removed and 6th axis speed increased to 360 degrees/second. Doosan Robotics’ continued priority on optimal safety across its solutions is also fully present in the new P3020. This includes achieving the highest PL (e) and Cat 4 safety ratings to ensure both a max-powered and max-safety experience for users.
The motion platform company’s newly unveiled P3020 palletization cobot will be on full display (Booth #850) at Automate 2024 (May 6-9), alongside the company’s ready-to-sell solutions with best-in class partners in Machine Tending, Palletizing, Welding, and Food & Beverage services.
Driven by its vision to elevate everyday experiences and redefine labor workflows, Doosan Robotics provides a wide, exceptional range of AI cobots aimed to bring about a paradigm shift across various sectors, such as palletizing, manufacturing, logistics, food & beverage, architecture, and service industries. These cutting-edge solutions transcend the constraints of conventional robotics, adeptly maneuvering through intricate scenarios while infusing tasks with enhanced efficiency, safety, and ingenuity. Moreover, the AI system boasts continuous learning capabilities, effortlessly updating its model by autonomously downloading required modules for smooth integration.
“As a motion platform company, Doosan Robotics is meeting the ever-growing need for cobots to mimic human motion, powerfully and safely,” said William Ryu, CEO at Doosan Robotics. “The robotics industry continues to grow at an exponential pace and our lineup of software, cobots and AI differentiates us in our mission to develop cobots with a ‘max-powered, max-efficiency, max-safety’ mindset.”
For more details and videos on the new P3020 cobot by Doosan Robotics, please visit the Doosan Robotics YouTube channel here. For more info, images, and other assets regarding Doosan Robotics’ Automate 2024 overall presence, please visit the press kit here or contact [email protected].
ABOUT DOOSAN ROBOTICSDoosan Robotics is a global leader in collaborative robot solutions, embodying the principle of ‘Innovation in every motion, revolutionizing the way we work.’ Doosan robots, known for world-class safety and precision, enhance task efficiency across various sectors from manufacturing to service, enabling people to focus on more valuable work. More information about Doosan Robotics is available at https://www.doosanrobotics.com/en/.
Photo – https://mma.prnewswire.com/media/2405465/Doosan_Robotics_Unveils_Max_Powered_PRIME_SERIES.jpg
Logo – https://mma.prnewswire.com/media/2403399/Doosan_Robotics_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/doosan-robotics-unveils-max-powered-prime-series-of-collaborative-robots-at-automate-2024-302136958.html
Artificial Intelligence
Enghouse announces expansion of our cloud contact center technology in the Middle East through our partnership with Voxtron
MARKHAM, ON, May 6, 2024 /PRNewswire/ — Enghouse Interactive, a global leader in contact center and video technology solutions, is proud to announce a strategic partnership with Voxtron, the premier provider of call center solutions in the Middle East. This collaboration is marked by Voxtron’s introduction of the innovative Voxvantage Cloud Contact Center as a Service (CCaaS), leveraging advanced contact center technology from Enghouse.
The Official Launch will take place at the Grand Hyatt Dubai. Industry participants and media are invited to RSVP to attend by emailing [email protected].
Date: 9th May 2024 Time: 6:00 PM to 10:00 PM Venue: Grand Hyatt Dubai, RSVP: [email protected]
Voxvantage CCaaS marks a significant advancement for Enghouse Systems, underscoring a commitment to enhancing customer experiences throughout the region. Hosted on the robust data center infrastructure of Moro Hub, Voxtron guarantees exceptional reliability, security, and scalability.
The launch will feature distinguished speakers, including Tracy Reynolds, Canadian Consul General in Dubai, Vincent Mifsud, Global President of Enghouse Systems, and Arif AlMalik, Chief Digital Products Officer of Moro Hub. They will explore the transformative potential of contact solutions in improving customer experience (CX) in the Middle East.
Mr. Mifsud expressed his enthusiasm about the partnership, stating, “We are excited to collaborate with Voxtron and Moro Hub. This partnership is crucial as we aim to provide our call center technology, enhance our presence across the Middle East by providing customers with leading technology that improves customer experiences.”
The event will also offer excellent networking opportunities and insightful discussions on the future of customer engagement solutions.
About Enghouse Interactive:
Enghouse Interactive, a subsidiary of Enghouse Systems Limited, is a global leader in contact center software and video technology solutions offering its customers and partners the valuable advantage of choice. Enghouse Interactive empowers businesses to transform contact centers from cost centers into powerful growth engines by simplifying complex integrations through open standards and supporting various telephony technologies to ensure seamless customer accessibility across channels and locations.
About Voxtron:
Voxtron Middle East is headquartered in Dubai, U.A.E., and has a global presence with offices and affiliates in Qatar, India, Germany, Austria, Belgium, Italy, Turkey, Tunisia, Hong Kong, Portugal, and Thailand. Voxtron has been delivering cost-effective customer engagement optimization solutions in collaboration with leading technology vendors such as Enghouse Interactive, SAGE, Verint, and Clarabridge, for over a decade. This extensive portfolio positions Voxtron as a unique provider capable of delivering complete, fully-featured solutions to customers and partners.
Enghouse Video Contact: Tim Peters, VP, Global Demand Generation Leader, Enghouse Systems, [email protected]
View original content:https://www.prnewswire.co.uk/news-releases/enghouse-announces-expansion-of-our-cloud-contact-center-technology-in-the-middle-east-through-our-partnership-with-voxtron-302136981.html
Artificial Intelligence
Appdome Named “Editor’s Choice for Mobile App Security” in Coveted Global InfoSec Awards during RSA Conference 2024
Appdome Wins in 12th Annual Global InfoSec Awards at #RSAC 2024
SAN FRANCISCO, May 6, 2024 /PRNewswire/ — Appdome, the mobile app economy’s one-stop shop for mobile app defense, is proud to announce it has won Editor’s Choice for Mobile App Security from Cyber Defense Magazine (CDM), the industry’s leading electronic information security magazine.
The Appdome platform is the first and only full lifecycle mobile app defense platform to automatically build, monitor and respond with any or all of 300+ mobile app defenses including security, anti-fraud, anti-malware, anti-cheat, anti-bot, geo compliance and social engineering for any mobile app in minutes with no SDK or coding required – all within the CI/CD pipeline. As a mobile app security engine for DevOps, Appdome enables mobile app developers, even those lacking security expertise, with an easy and fast way to secure all Android & iOS apps without any additional work. By automating security in the mobile pipeline, Appdome eliminates the cost and complexity of manually coding security, fraud and compliance features so mobile brands can confidently ship secure mobile apps faster with always-on protections to meet their critical mobile business needs.
“We’re proud to be recognized as Editor’s Choice for Mobile App Security by Cyber Defense Magazine in its 12th year of awarding the most prestigious and coveted cybersecurity award in the world,” said Tom Tovar, co-creator and CEO of Appdome. “With organizations battling unnecessary complexity from point products, the Appdome platform approach to mobile defense is leading the way to unify 300+ protections across security, anti-fraud, bot defense, mobile EDR, and compliance for all internal (employee) and external (consumer) facing mobile applications under a single pane of glass.”
“We scoured the globe looking for cybersecurity innovators that could make a huge difference and potentially help turn the tide against the exponential growth in cyber-crime. Appdome is absolutely worthy of Editor’s Choice for Mobile App Security coveted award and consideration for deployment in your environment,” said Yan Ross, Global Editor of Cyber Defense Magazine.
Appdome and all award winners located here: http://www.cyberdefenseawards.com/
Appdome continues to deliver waves of innovation in 2024 including:
Appdome Unveils World’s first Agentless Mobile EDR & MTDAppdome MOBILEBot ProtectionAppdome World’s First Real-Time Defense for Social EngineeringAppdome Revolutionizes Geo Defense for Mobile BrandsPlease join Appdome at the RSA Conference 2024 booth #2339 to see the award winning Appdome Platform in action!
Learn more at www.appdome.com.
About AppdomeThe Appdome mission is to protect every mobile app in the world and the people who use mobile apps in their lives and at work. Appdome provides the mobile industry’s only Unified Mobile App Defense platform, powered by a patented mobile coding engine, Threat-Events™ Threat-Aware UX/UI Control and ThreatScope™ Mobile XDR. Using Appdome, mobile brands eliminate complexity, ship faster and save money by delivering 300+ Certified Secure™ mobile app security, anti-malware, anti-fraud, mobile anti-bot, anti-cheat, geo compliance, MiTM attack prevention, code obfuscation, social engineering and other protections in Android and iOS apps with ease, inside the mobile DevOps and CI/CD pipeline. Leading financial, healthcare, government and m-commerce brands use Appdome to protect Android and iOS apps, mobile customers and mobile businesses globally. Appdome holds several patents including U.S. Patents 9,934,017 B2, 10,310,870 B2, 10,606,582 B2, 11,243,748 B2 and 11,294,663 B2. Additional patents pending.
About Cyber Defense MagazineCyber Defense Magazine is the premier source of cyber security news and information for InfoSec professions in business and government. We are managed and published by and for ethical, honest, passionate information security professionals. Our mission is to share cutting-edge knowledge, real-world stories and awards on the best ideas, products, and services in the information technology industry. We deliver electronic magazines every month online for free, and special editions exclusively for the RSA Conferences. CDM is a proud member of the Cyber Defense Media Group. Learn more about us at https://www.cyberdefensemagazine.com and visit https://www.cyberdefensetv.com and https://www.cyberdefenseradio.com to see and hear some of the most informative interviews of many of these winning company executives. Join a webinar at https://www.cyberdefensewebinars.com and realize that infosec knowledge is power.
Logo – https://mma.prnewswire.com/media/772169/4688418/AppDome_Logo_9_27_23.jpg
View original content:https://www.prnewswire.co.uk/news-releases/appdome-named-editors-choice-for-mobile-app-security-in-coveted-global-infosec-awards-during-rsa-conference-2024-302136929.html
-
Artificial Intelligence3 days ago
CleverTap launches Clever.AI, the AI-Driven Edge for Customer Engagement & Retention
-
Artificial Intelligence7 days ago
SUNRATE partners with YeePay to empower Chinese companies to navigate global expansion
-
Uncategorized7 days ago
Intel unveils AI-Platform Innovation for Paris 2024
-
Uncategorized4 days ago
Improving the Developer Journey in Crafting Artificial Intelligence Applications
-
Artificial Intelligence5 days ago
Appdome Unveils World’s First Agentless Mobile EDR & MTD
-
Uncategorized4 days ago
Unveiling the Complex Psychological Implications of Artificial Intelligence
-
Artificial Intelligence4 days ago
Bitrue expands Bitcoin Runes Offerings with GPTV Listing and Staking Options
-
Artificial Intelligence4 days ago
5G Enterprise Market Projected to Reach $115.81 billion by 2030 – Exclusive Report by 360iResearch